Project Grant R01HL092992

Federal Project Grant Award Summary The University of Virginia received a $1.46 million Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded on April 14, 2026, with a three-year performance period concluding April 13, 2029. The project, titled "Preserving Lung Integrity and Harnessing Inflammation to Treat Vesicant-Induced Lung Injury," focuses on developing therapeutic approaches to...

This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,387 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2025 through April 30, 2029, funds research investigating lung vascular Group 3 Innate Lymphoid Cell (ILC3) subpopulations and their roles in antibacterial immunity and vascular regeneration. The...

Federal Project Grant Award Summary Weill Medical College of Cornell University received a $791,503 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2029. This research initiative investigates novel roles of the thrombin receptor Protease Activated Receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS)....

Federal Project Grant Award Summary Vanderbilt University Medical Center received a $319,248 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of July 31, 2030. The grant funds research investigating hypoxia-inducible factor (HIF)-driven modulation of alveolar regeneration to address idiopathic pulmonary fibrosis (IPF). The research deliverables include...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $744,880 to the University of Colorado-Denver through the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a four-year research project running from September 1, 2025, through May 31, 2029. The research investigates epimetabolic regulation of macrophage activation during acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), focusing on how lactate produced by...

The University of California, San Francisco received a $2.44 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to target the ATP receptor P2RX4 for pulmonary fibrosis. The four-year award beginning July 1, 2021 will support research into medical solutions for pulmonary disease on the battlefield and in veterans. As part of the award, Baylor College of Medicine will receive sub-award funding to conduct clinical...

This $3,757,391 Project Grant award from the U.S. Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the development of a field-use therapeutic for pulmonary injuries from trauma or chemical exposure. The awardee, Ceria Therapeutics Inc., is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The funding will enable Ceria Therapeutics to advance its...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $178,846 Project Grant to the University of California, San Diego, effective August 1, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a prospective clinical research study investigating optimal ventilator management strategies for patients with Acute Respiratory Distress Syndrome (ARDS) on veno-venous extracorporeal membrane oxygenation...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...